Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I

References

• Kudoh S, Keicho N. Diffuse panbronchiolitis. Semin Respir Criti Care Med. 2003;24(5):607–18.
   PubMed Web of Science ®Google Scholar
• Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest. 2004;125(2 Suppl):52S–60S.
   PubMedGoogle Scholar
• Park CS, Park YS, Park YJ, Cho JH, Kang JM, Kim SY. The inhibitory effects of macrolide antibiotics on bone remodeling in chronic rhinosinusitis. Otolaryngology–head and neck surgery. 2007;137(2):274–9.
   PubMedGoogle Scholar
• Inoue S, Nakase H, Matsuura M, Ueno S, Uza N, Kitamura H, et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J Gastroenterol Hepatol. 2007;22(7):984–8.
   PubMedGoogle Scholar
• Polat M, Lenk N, Yalcin B, Gur G, Tamer E, Artuz F, Alli N. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol. 2007;32(3):295–7.
   PubMedGoogle Scholar
• Fraschini F, Scaglione F, Ferrara F, Marelli O, Braga PC, Teodori F. Evaluation of the immunostimulating activity of erythromycin in man. Chemotherapy. 1986;32(3):286–90.
   PubMedGoogle Scholar
• Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis. 1989;159(5):966–73.
   PubMedGoogle Scholar
• Chantot JF, Bryskier A, Gasc JC. Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo). 1986;39(5):660–8.
   PubMedGoogle Scholar
• Young RA, Gonzalez JP, Sorkin EM. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1989;37(1):8–41.
   PubMedGoogle Scholar
• Noma T, Hayashi M, Yoshizawa I, Aoki K, Shikishima Y, Kawano Y. A comparative investigation of the restorative effects of roxithromycin on neutrophil activities. Int J Immunopharmacol. 1998;20(11): 615–24.
   PubMedGoogle Scholar
• Wakita H, Tokura Y, Furukawa F, Takigawa M. The macrolide antibiotic, roxithromycin suppresses IFN-γ-mediated immunological functions of cultured normal human keratinocytes. Biol Pharm Bull. 1996;19(2):224–7.
   PubMedGoogle Scholar
• Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Inhibition of human T-lymphocyte activation by macrolide antibiotic, roxithromycin. Life Sci. 1992;51(24):PL231–6.
   Google Scholar
• Yoshimura T, Kurita C, Yamazaki F, Shindo J, Morishima I, Machida K, et al. Effects of roxithromycin on proliferation of peripheral blood mononuclear cells and production of lipopolysaccharide-induced cytokines. Biol Pharm Bull. 1995;18(6):876–81.
   PubMedGoogle Scholar
• Urasaki Y, Nori M, Iwata S, Sasaki T, Hosono O, Kawasaki H, et al. Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages. J Rheumatol 2005;32:1765–74.
   PubMed Web of Science ®Google Scholar
• Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999;11:417–26.
   PubMed Web of Science ®Google Scholar
• Rosloniec EF, Cremer M, Kang A, Myers LK. Collagen-induced arthritis. In: Coligan JE, Kruisbeek AM, Margulies AH, Shevach EM, Strober W, eds. Current Protocols in Immunology.
   Google Scholar
• Endo Y, Hirahara K, Yagi R, Tumes DJ, Nakayama T. Pathogenic memory type Th2 cells in allergic inflammation. Trends Immunol. 2014;35(2):69–78.
   PubMedGoogle Scholar
• Christie D, Zhu J. Transcriptional Regulatory Networks for CD4 T Cell Differentiation. Curr Top Microbiol Immunol. 2014;381:125–72.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517.
   PubMed Web of Science ®Google Scholar
• Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–33.
   PubMedGoogle Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol. 2008;9(6):641–9.
   PubMedGoogle Scholar
• Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345–50.
   PubMedGoogle Scholar
• Glant TT, Kamath RV, Bardos T, Gal I, Szanto S, Murad YM, et al. Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor alpha-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum. 2002;46(8):2207–18.
   PubMedGoogle Scholar
• Bayliss MT, Howat SL, Dudhia J, Murphy JM, Barry FP, Edwards JC, Day AJ. Up-regulation and differential expression of the hyaluronan-binding protein TSG-6 in cartilage and synovium in rheumatoid arthritis and osteoarthritis. Osteoarthritis Cartilage. 2001;9(1):42–8.
   PubMedGoogle Scholar
• Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci. 2003;116(Pt 10):1863–73.
   PubMedGoogle Scholar
• Venkatachalam K, Venkatesan B, Valente AJ, Melby PC, Nandish S, Reusch JE, et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-alpha (TNF-α)-stimulated cardiac fibroblast proliferation but inhibits TNF-α-induced cardiomyocyte death. J Biol Chem. 2009;284(21):14414–27.
   PubMedGoogle Scholar
• Mori H, Nishida K, Ozaki T, Inoue H, Setsu K, Tsujigiwa H, et al. Expression of WISP-1 (ccn4), WISP-2 (ccn5) and WISP-3 (ccn6) in rheumatoid arthritis synovium evaluated by DNA microarrays. J Hard Tissue Biol. 2006;15(3):89–95.
   Google Scholar
• Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Roxithromycin suppresses involucrin expression by modulation of activator protein-1 and nuclear factor-κB activities of keratinocytes. J Dermatol Sci. 2005;39(3):175–82.
   PubMedGoogle Scholar
• Asano K, Tryka E, Cho JS, Keicho N. Macrolide therapy in chronic inflammatory diseases. Mediators Inflamm. 2012;2012:692352.
   PubMedGoogle Scholar
• Du Q, Geller DA. Cross-Regulation Between Wnt and NF-κB Signaling Pathways. For Immunopathol Dis Therap 2010;1(3):155–81.
   PubMedGoogle Scholar
• Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol. 1999;162(3):1246–51.
   PubMedGoogle Scholar
• Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42(5):963–70.
   PubMedGoogle Scholar
• Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol. 1997;107(3):507–12.
   PubMedGoogle Scholar
• Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993;261(5126):1328–30.
   PubMedGoogle Scholar
• Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, Okumura K, et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol. 2002;169(8):4332–9.
   PubMedGoogle Scholar
• Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7–1 and B7–2. Eur J Immunol. 1996;26(10):2320–8.
   PubMedGoogle Scholar
• Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol. 2000;30(10):2815–23.
   PubMedGoogle Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New Engl J Med. 2000;343(22):1594–602.
   Google Scholar
• Kondo Y, Iizuka M, Wakamatsu E, Yao Z, Tahara M, Tsuboi H, et al. Overexpression of T-bet gene regulates murine autoimmune arthritis. Arthritis Rheum. 2012;64(1):162–72.
   PubMedGoogle Scholar
• Product Information, RULIDE® & RULIDE® D. http://www.sanofi.com.au/products/aus_pi_rulide.pdf; 2012.
   Google Scholar
• Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1173–5.
   PubMedGoogle Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13): 3183–94.
   PubMedGoogle Scholar
• Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116(5):1310–6.
   PubMedGoogle Scholar